These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36507526)

  • 1. Mechanistic insights into the peroxisome proliferator-activated receptor alpha as a transcriptional suppressor.
    Yagai T; Nakamura T
    Front Med (Lausanne); 2022; 9():1060244. PubMed ID: 36507526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
    Yu DD; Van Citters G; Li H; Stoltz BM; Forman BM
    Bioorg Med Chem; 2021 Jul; 41():116193. PubMed ID: 34022528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    Pawlak M; Lefebvre P; Staels B
    J Hepatol; 2015 Mar; 62(3):720-33. PubMed ID: 25450203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
    Zhou S; You H; Qiu S; Yu D; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
    Biomed Pharmacother; 2022 Oct; 154():113577. PubMed ID: 35988420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?
    Theys C; Lauwers D; Perez-Novo C; Vanden Berghe W
    Biomedicines; 2022 Nov; 10(12):. PubMed ID: 36551797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
    Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
    Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.
    Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B
    J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver.
    Kersten S; Stienstra R
    Biochimie; 2017 May; 136():75-84. PubMed ID: 28077274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation.
    Dai L; Feng Z; Zha R; Cheng K; Wen X; Sun H; Yuan H
    J Chem Inf Model; 2020 Mar; 60(3):1717-1727. PubMed ID: 32027126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
    Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
    Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting nuclear receptors for the treatment of fatty liver disease.
    Tanaka N; Aoyama T; Kimura S; Gonzalez FJ
    Pharmacol Ther; 2017 Nov; 179():142-157. PubMed ID: 28546081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.